There is a reason why vaccine makers and bought-off politicians are racing to vaccinate 100 million Americans by July 4th.  If prior population studies are any indication, by July 2021 it is likely a safer and more effective vaccine than RNA vaccines (Pfizer/Moderna) will be revealed in a large-group placebo vs inoculum study taking place in Canada.

If you are in torment over whether to vaccinate against COVID-19 or not, or forced to mull over vaccination because your employer demands you submit to immunization as a condition of employment, hold on, at least till July 2021, when the results of a major vaccine study will likely be revealed.  Though existing data is so compelling one would wonder why anyone fearful of COVID19 would hesitate to undergo immunization immediately.

A major drawback of the RNA vaccines now being pushed upon wary Americans is that they pose the problem of antibody dependent enhancement (ADE) – – your own antibodies attack your lungs and other internal organs.  ADE is usually a delayed reaction.  And ADE is beginning to occur among vaccinated populations.  ADE strikes younger populations. According to some reports, vaccine-induced antibodies against COVID-19 are not providing lasting immunity.  RNA vaccines largely activate antibodies.

T-cells are known to protect against severe infection and re-infection.  T-cell memory provides lasting immunity.  T-cell directed vaccines stimulate clearance of viruses and avoid antibody-dependent enhanced disease.

These same researchers reveal there already is a proven safe and effective vaccine that protects against COVID-19 via activation of T-cells – – the Bacille Calmette-Guerin (BCG) vaccine for another infectious lung disease — tuberculosis.  It is derived from a mycobacterium (mycobacterium bovis) found in cattle. It is a "live" but attenuated bacterium.

BCG vaccine mechanism: trained immunity

The BCG vaccine is not widely used in the US.